Media headlines about Heron Therapeutics (NASDAQ:HRTX) have trended somewhat negative recently, according to AlphaOne Sentiment. The research group, a service of Accern, ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heron Therapeutics earned a news sentiment score of -0.03 on AlphaOne’s scale. AlphaOne also assigned news articles about the biotechnology company an impact score of 32 out of 100, indicating that recent media coverage is unlikely to have an impact on the company’s share price in the near term.
Here are some of the news stories that may have effected AlphaOne Sentiment Analysis’s rankings:
- Heron Therapeutics, Inc. (NASDAQ:HRTX) Needle Ticks -6.71% For the Week – Concord Register (concordregister.com)
- HC Stocks to Path=> Heron Therapeutics Inc (NASDAQ:HRTX), OHR Pharmaceutical Inc (NASDAQ:OHRP) – usstockjournal (usstockjournal.com)
- Research Analysts Offer Predictions for Heron Therapeutics Inc’s Q2 2017 Earnings (HRTX) (americanbankingnews.com)
- Heron Therapeutics Inc (HRTX) Rating Reiterated by Noble Financial (americanbankingnews.com)
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 14.10 on Friday. The firm has a 50-day moving average of $14.75 and a 200 day moving average of $14.57. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $24.00.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The business had revenue of $3.63 million during the quarter, compared to analysts’ expectations of $1.96 million. Equities analysts anticipate that Heron Therapeutics will post ($3.63) EPS for the current year.
A number of analysts have issued reports on HRTX shares. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Jefferies Group LLC reissued a “buy” rating and issued a $29.00 price objective on shares of Heron Therapeutics in a research note on Monday, April 10th. Needham & Company LLC initiated coverage on shares of Heron Therapeutics in a research note on Monday, February 27th. They issued a “buy” rating and a $28.00 price objective for the company. Aegis reissued a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. Finally, Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Heron Therapeutics has a consensus rating of “Buy” and a consensus target price of $34.50.
COPYRIGHT VIOLATION WARNING: “Heron Therapeutics (HRTX) Getting Somewhat Critical Media Coverage, Report Finds” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://transcriptdaily.com/2017/05/20/heron-therapeutics-hrtx-receives-news-sentiment-score-of-0-03-updated-updated-updated.html.
In other Heron Therapeutics news, VP Kimberly Manhard sold 21,542 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $15.33, for a total value of $330,238.86. Following the completion of the transaction, the vice president now owns 5,250 shares in the company, valued at approximately $80,482.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.31% of the stock is owned by corporate insiders.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.